Novo Nordisk (NOVOB.DK) shares are losing 20% after the pharmaceutical giant, known for its obesity drugs Ozempic and Wegova, released disappointing clinical trial data for its experimental obesity drug CagriSema. Patients treated with Novo's next-generation weight-loss drug CagriSema lost an average of 22.7% of their weight after 68 weeks, falling short of the 25% goal the drugmaker expected. About 40% of patients lost 25% or more of their body weight.

The company's shares are trading at their lowest since August 2023. Source: xStation
CME Group shares fall amid selling pressure 🚩 Why it could be a warning sign for Wall Street?
Market Wrap: Europe is catching up🔼 Will Eurozone CPI data determine the ECB’s rate hike?
Economic Calendar: Key readings on the schedule (02.06.2026)
Morning Briefing: Inconsistent messages ahead of key data (02.06.2026)